Accessibility Menu
Camp4 Therapeutics Stock Quote

Camp4 Therapeutics (NASDAQ: CAMP)

$6.10
(-2.8%)
-0.17
Price as of March 10, 2026, 9:51 a.m. ET

KEY DATA POINTS

Current Price
$6.14
Daily Change
(-2.8%) $0.17
Day's Range
$5.90 - $6.38
Previous Close
$6.28
Open
$6.38
Beta
1.56
Volume
52,222
Average Volume
250,016
Market Cap
$326M
Market Cap / Employee
$6.27M
52wk Range
$1.31 - $7.75
Revenue
N/A
Gross Margin
0.53%
Dividend Yield
N/A
EPS
-$2.57
CAPs Rating
N/A
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Camp4 Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CAMP+49.76%N/AN/A-41%
S&P+17.78%+74.31%+11.75%+17%

Camp4 Therapeutics Company Info

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

News & Analysis

Financial Health

General

Q4 2025YOY Change
Revenue$348.00K-46.6%
Gross Profit-$24.00K-110.3%
Gross Margin-6.90%-42.8%
Market Cap$318.03M202.2%
Market Cap / Employee$6.63M0.0%
Employees48-12.7%
Net Income-$40,284.00K-203.4%
EBITDA-$12,404.00K8.9%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q4 2025YOY Change
Net Cash$110.86M73.1%
Accounts Receivable$155.00K0.0%
Inventory00.0%

Liabilities

Q4 2025YOY Change
Long Term Debt$1.69M-69.7%
Short Term Debt$286.00K-91.0%

Ratios

Q4 2025YOY Change
Return On Assets-82.00%-4.3%
Return On Invested Capital-75.55%0.1%

Cash Flow

Q4 2025YOY Change
Free Cash Flow$6.29M140.5%
Operating Free Cash Flow$6.29M141.2%

Valuation

MetricQ1 2025Q2 2025Q3 2025Q4 2025YoY Change
Price to Book1.280.571.514.90-839.94%
Price to Sales53.399.7221.5290.96-43.61%
Price to Tangible Book Value1.280.571.514.90-839.94%
Enterprise Value to EBITDA-3.100.21-1.01-16.87360.81%
Return on Equity-102.0%-188.2%-172.7%-145.1%-
Total Debt$7.96M$7.22M$6.35M$1.97M-77.40%

No results found

No podcast episodes available.

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.